| Baxter awarded UK influenza vaccine contract | Posted on 17/08/2007 in Pharmaceutical Company Product News Baxter International has announced that UK-based European subsidiary has entered into an agreement with the Department of Health for the advanced supply of influenza vaccine, which includes an option to purchase the vaccine if the World Health Organisation declares a pandemic.
The company reports that its pandemic vaccine is manufactured in a serum-free vero cell-based system, which offers benefits when compared to standard egg-based technology, including a speedier initiation of the process and replicable high yields to facilitate a quick response to new emerging virus strains.
Baxter is currently cooperating with a number of governments worldwide on pandemic preparation, having delivered several million doses of its H5N1 pre-pandemic vaccine across the globe.
Kim Bush, president of the vaccines business at Baxter, said: "We are proud to provide the necessary technology, manufacturing capability and other resources to assist the Department of Health in its efforts to protect the UK population from the threat of a flu pandemic."
The firm notes that the composition and structure of its antigen composition is similar to the pathogen occurring in the natural world and operates by inducing an immune response in people that mimics the natural defence against a virus, without the need for adjuvants.
Last month, Baxter presented preliminary phase I/II clinical study results of its vero cell-based influenza vaccine candidate at the Options of the Control of Influenza VI Conference in Toronto, with the vaccine showing good tolerability and exhibiting a strong antibody response in all patients.Other news stories from 17/08/2007
Read more in the Zenopa News Archive
How this news is generated
|  |
|
